Provention Bio is part of the healthcare sector and is in the biotechnology industry. The company CEO is Ashleigh Palmer. Previous Intraday Performance:
The PRVB shares had a previous change of 8.62% which opened at 2.94 and closed at 3.15. It moved to an intraday high of 3.20 and a low of 2.89.
SeekingAlpha: FARO, HOLI, ZGNX and FIXX among notable midday movers Historical Performance:
Over the last five trading days, PRVB shares returned 14.13% and in the past 30 trading days it returned 32.35%. Over three months, it changed 41.89%. In one year it has changed -34.51% and within that year its 52-week high was 8.00 and its 52-week low was 1.52. PRVB stock is 107.24% above its 52 Week Low.
Our calculations result in a 200 day moving average of 2.97 and a 50 day moving average of 2.44. Right now, PRVB stock is trading 6.04% above its 200 day moving average.
SeekingAlpha: Provention Bio commences late-stage study of T1D candidate teplizumab Liquidity:
The company has a market cap of $117.7m with 37.4m shares outstanding and a float of 30.2m shares. Trading volume was 180,123 shares and has experienced an average volume of 45,805 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock . Earnings:
The last annual reported EPS for Provention Bio was -0.3 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.19.
The next earnings report will be: 05-02-2019
The growth of the EPS is critical in understanding the current valuation of Provention Bio. Indicators Also to Watch:
Based on the latest filings, there is 2.30% of institutional ownership.
I calculated the beta to be 3.34
PR Newswire: Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -99.30%, return on assets is -64.47% and price-to-book is 1.82. Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Click here to view original web page at Stock to Watch: Provention Bio (NASDAQ: PRVB)